FINWIRES · TerminalLIVE
FINWIRES

Biofuels Update: Feedstock Futures Mixed; Soybean Oil, Palm Oil Diverge From Crude Oil

By

-- Major biofuel feedstock futures were mixed on Monday, as Chicago soybean futures rose while Chicago soybean oil and Malaysian palm oil slipped despite higher crude oil prices.

The May soybean contract on the Chicago Board of Trade rose for a second straight session by 0.19% to $11.66 per bushel. The May soybean oil contract fell 0.21% to 71.76 cents per pound.

Soybean oil diverged from crude oil's upward movement over uncertainties surrounding what will come next for potential US-Iran peace talks.

Meanwhile, rainfall expected in parts of the US this week that could slow planting, provided a boost to soybean prices.

However, increasing global supply, with Brazil's record soybean harvest almost completed, weighed on the entire soybean complex.

"The fundamental outlook for bumper crops in South America remains unchanged, global soybean supply is expected to stay loose, and there is a lack of key bullish factors to drive a trending market in the short term," according to price reporting agency MySteel.

"Overall, US soybeans are seeing a balance between strong crush demand and supply pressure from South America, presenting a rangebound pattern with upside pressure and downside support," MySteel said.

Rangebound price movements and chart resistance will prevent July soybean futures from going above the $11.80 per bushel mark, Darren Frye of consulting firm Water Street Solutions told Ag Web.

Going forward, the market is expected to shift its attention to the US-China summit in mid-May, as traders await hints of additional demand from China, Mark Soderberg of ADM Investor Services said.

In Asia, Malaysian palm oil futures slipped more than 1% on Monday, pulling away from crude oil prices, due to weaker exports and a 0.36% strengthening in the Malaysian ringgit versus the US dollar.

The Bursa Malaysia Derivatives' May and June crude palm oil contracts closed at 4,465 Malaysian ringgit ($1,129.38) per metric ton and 4,505 ringgit/mt, respectively.

Malaysian shipments for the April 1-25 period reportedly declined 15.7% from a month earlier, according to cargo surveyors cited by Trading Economics.

This followed a 29.1% year-over-year rise in Q1 exports, as buyers advanced purchases due to the expected surge in shipping costs and as volumes of rival Indonesian cargoes softened due to higher export levies, according to the Malaysian Palm Oil Council.

Indonesia's move to raise its palm-based biodiesel blending to 50% from 40% beginning July 1 could lift Malaysian exports going forward.

The MPOC said Indonesia's B50 program could absorb an additional 3 million metric tons per year of palm oil.

Annual domestic consumption in Thailand could also increase by 350,000 metric tons as the country moves to B7 from B5, while demand in Malaysia could rise by 300,000 mt as the government raises its biodiesel blend to B15 from B10.

Increasing biofuel demand, elevated crude oil prices, and supply risks from the potential development of an El Nino weather trend will support palm oil prices, with the MPOC projecting them at around 4,500 ringgit/mt in the near term.

"However, further gains are likely to be capped by softer export demand amid inflation and weaker economic growth in key importing countries, alongside rising stocks as palm oil production gradually enters its seasonal peak," the MPOC said.

According to Jim Teh, senior palm oil trader at Interband Group of Co., as cited by Bernama, palm oil prices could trade between 4,200 ringgit/mt and 4,300 ringgit/mt this week due to profit taking.

In the US, the May-dated ethanol futures on the NYMEX jumped 1.95% to about $1.96 per gallon on Friday.

Related Articles

International

New Zealand's Q1 Unemployment Rate Expected to Stay Steady, ANZ Says

New Zealand's first-quarter unemployment rate is expected to remain steady at 5.4%, slightly lower than the previous forecast of 5.5%, according to a report by ANZ released on Wednesday.ANZ increased its quarterly employment growth forecast by 0.1 percentage points to 0.3%, with employment growth appearing to have held onto a little more momentum in March than previously anticipated, the report said.Upcoming data on hours paid and hours worked may indicate some signal around the risks to the first-quarter GDP forecast of 0.8% quarter on quarter, though the recent oil shock likely won't show up yet since the labor market is typically the last sector to react to changing economic conditions.First-quarter labor market data is expected to show that the market had enough excess capacity to act as a buffer against the recent oil shock, limiting the risk of labor costs driving up inflation in the near term.

$^NZ50
International

India's Industrial Production Slows to 4.1% in March

India's production growth, measured by the Index of Industrial Production, slowed to 4.1% in March from 5.2% in February, according to data released by the Ministry of Statistics and Programme Implementation (MoSPI) on Tuesday.In March 2025, India's IIP growth rate was at 3.9%.The quick estimates of IIP came in at 173.2 in March, up from 166.3 in the same month in 2025.The manufacturing sector, which carries the largest weight in the index, grew at 4.3% in March from 4.0% a year earlier. It was, however, lower than the 5.9% growth in February.Mining output grew 5.5% in March against 1.2% in the corresponding period of the previous year. Electricity production, however, fell to 0.8%, compared with 7.5% in the year-ago period.The indices of industrial production for the mining, manufacturing, and electricity sectors for March stood at 166.8, 169.4, and 221.3, respectively.

$^BSE$^NSEI
Asia

Anteris Technologies Secures US Medicare Reimbursement Eligibility for PARADIGM Trial

Anteris Technologies (ASX:AVR) said it has secured US Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a Centers for Medicare and Medicaid Services (CMS) national coverage policy, according to a Wednesday Australian bourse filing.The PARADIGM Trial is evaluating the safety and effectiveness of the DurAVR transcatheter heart valve (THV) compared to transcatheter aortic valve replacements (TAVRs), with DurAVR THV being Anteris' product to treat aortic stenosis, a potentially life-threatening condition resulting from the narrowing of the aortic valve, the filing added.The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation.The company said that securing this reimbursement eligibility is expected to facilitate US site activation and accelerate operational momentum across participating centers.The company's shares rose 2% in recent Wednesday trade.

$ASX:AVR